Mirum Pharmaceuticals (MIRM) is on the Move, Here's Why the Trend Could be Sustainable
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Mirum Pharmaceuticals (MIRM) is Your Friend, Here's Why
Mirum Pharmaceuticals (MIRM) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Mirum Pharmaceuticals (MIRM) Upgraded to Buy: What Does It Mean for the Stock?
Mirum Pharmaceuticals (MIRM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results
Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
Mirum Pharmaceuticals (MIRM) Is a Great Choice for 'Trend' Investors, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Mirum Pharmaceuticals (MIRM) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Top 5 Commercial Biotech Buyout Candidates: Mirum Pharmaceuticals (No. 3)
Mirum Pharma: Buy At Dips For Volixibat Potential
Mirum Pharma has three approved products and a promising pipeline, with volixibat showing superior interim data for PBC compared to competitors. It is a buy for volixibat's potential, which is 2-3 years away from approval, but supported in the interim by the other approved drugs. Financially, Mirum has a market cap of $2bn, a cash balance of $294mn, and a cash runway of over 12-15 quarters.
Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
Mirum Shares Surge More Than 90% in 6 Months: Here's Why
MIRM's lead drug, Livmarli, is driving revenues and the momentum is likely to continue. The company's efforts to build its pipeline beyond Livmarli also hold promise.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2024 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Q3 2024 Earnings Conference Call November 12, 2024 8:30 AM ET Company Participants Andrew McKibben - Vice President, Investor Relations Chris Peetz - Chief Executive Officer Peter Radovich - President & Chief Operating Officer Joanne Quan - Chief Medical Officer Eric Bjerkholt - Chief Financial Officer Conference Call Participants Gavin Clark-Gartner - Evercore ISI. Jessica Fye - JP Morgan Dae Gon Ha - Stifel Brian Skorney - Baird David Lebowitz - Citi Thomas Yip - H.C.
Mirum's Q3 Earnings Beat Estimates, 2024 Revenue View Raised
MIRM's third-quarter 2024 earnings and revenues surpass estimates. The company increases revenue guidance for 2024.
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q3 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.57 per share a year ago.
